Free Comment & Analysis from EP Vantage (last 3 months)

244 unique matching stories have been returned.

 
Click on headlines to view individual stories. To create a report, select stories using either the checkboxes or the 'Select All' buttons then select the required Print or Word Options from the menu above.
Free Content
  Date Headline Company
  September 07, 2010 EP Vantage Interview - Promedior building wide fibrosis platform Promedior
  September 06, 2010 Weekly Market Movers (to 3 Sep 2010) Inhibitex
  September 03, 2010 Event - Roche announces timely efficiency drive as Avastin decision looms Roche
  August 30, 2010 Weekly Market Movers (to 27 Aug 2010) ArQule
  August 26, 2010 Somaxon seeks to wake up Silenor launch with P&G alarm clock Somaxon Pharmaceuticals
  August 24, 2010 Kamada upgrades to Baxter to spearhead US move Kamada
  August 23, 2010 Weekly Market Movers (to 20 Aug 2010) Wockhardt
  August 20, 2010 Event – Savient's future awaits in Krystexxa approval decision Savient Pharmaceuticals
  August 17, 2010 EP Vantage Interview - Pragmatic Evotec takes on metabolic disease Evotec
  August 16, 2010 Event - Painful wait for ProStrakan on Abstral ProStrakan
  August 16, 2010 Weekly Market Movers (to 13 Aug 2010) Trubion Pharmaceuticals
  August 12, 2010 Merck calls a go-slow on oral vernakalant Cardiome Pharma
  August 10, 2010 No brainer for Endo as Penwest activists win the day Endo Pharmaceuticals
  August 09, 2010 Weekly Market Movers (to 6 Aug 2010) Movetis
  August 06, 2010 What partnering hopes for the industry's biggest unpartnered R&D assets? Clinical Data
  August 03, 2010 Merck continues to play down J&J arbitration but risk remains Merck & Co
  August 02, 2010 Weekly Market Movers (to 30 Jul 2010) Arena Pharmaceuticals
  July 29, 2010 Teva feeling effects of hybrid model Teva Pharmaceutical Industries
  July 27, 2010 EP Vantage Interview - Cerenis adds €40m to the HDL debate Cerenis Therapeutics
  July 26, 2010 Weekly Market Movers (to 23 Jul 2010) Momenta Pharmaceuticals
  July 22, 2010 NicOx gets the bad news on naproxcinod NicOx
  July 22, 2010 EP Vantage Interview - Calistoga eying registration trials with new funds Calistoga Pharmaceuticals
  July 21, 2010 Safety concerns narrow tanezumab’s potential further Pfizer
  July 19, 2010 Weekly Market Movers (to 16 Jul 2010) Northwest Biotherapeutics
  July 16, 2010 Vivus sheds more weight after Adcom rejection of Qnexa VIVUS
  July 14, 2010 EP Vantage Interview - Synta hotting up as Hsp90 data approaches Synta Pharmaceuticals
  July 13, 2010 EP Vantage Interview – New Genmab CEO aiming to turn tide in its favour Genmab
  July 12, 2010 Anti-coagulant products set to flow fastest Roche
  July 12, 2010 Weekly Market Movers (to 9 Jul 2010) VIVUS
  July 09, 2010 Kamada wins US approval for new AAT therapy as report prompts controversy Kamada
  July 07, 2010 Pharma industry cutting its R&D cloth to more sustainable levels Novartis
  July 05, 2010 EP Vantage Interview - Merrion partners into the future Merrion Pharmaceuticals
  July 05, 2010 EventAnalyzer: Weekly Market Movers (to 2 Jul 2010) Javelin Pharmaceuticals
  July 01, 2010 Big pharma continues to struggle in first half, Indian generics consolidate gains Novo Nordisk
  June 29, 2010 ADA - Roche's diabetes dreams fade as taspo data deteriorates Roche
  June 28, 2010 EventAnalyzer: Weekly Market Movers (to 25 Jun 2010) Biovail
  June 25, 2010 Sanofi snaffles novel diabetes drug Metabolex
  June 22, 2010 EP Vantage Interview - ImmunoGen awaiting validation ImmunoGen
  June 21, 2010 GW Pharma wins historic approval GW Pharmaceuticals
  June 21, 2010 EventAnalyzer: Weekly Market Movers (to 18 Jun 2010) Genmab
  June 18, 2010 Roche's diabetes blow prompts Amylin gain Roche
  June 15, 2010 Trubion's RA candidate gets the chop in Pfizer's R&D cull Trubion Pharmaceuticals
  June 14, 2010 EventAnalyzer: Weekly Market Movers (to 11 Jun 2010) PROLOR Biotech
  June 11, 2010 EP Vantage Exclusive - Hopp denies Wilex takeover ambitions Wilex
Comment
  Date Headline Company
  September 08, 2010 Bristol-Myers Squibb deals for new gentler and kinder interferon Bristol-Myers Squibb
  September 08, 2010 Forest receives unanimous backing for new antibiotic Forest Laboratories
  September 07, 2010 Pressure mounts to withdraw Avandia GlaxoSmithKline
  September 07, 2010 ProStrakan's debt pile casts dark shadow on drug delays ProStrakan
  September 06, 2010 Celldex reeling from Pfizer break up Celldex Therapeutics
  September 02, 2010 Mipomersen reports soaring phase III data but future still up in the air Isis Pharmaceuticals
  September 02, 2010 Obesity race tightens up as Takeda snares Contrave Orexigen Therapeutics
  September 01, 2010 Second motavizumab complete response could make AstraZeneca think twice AstraZeneca
  August 31, 2010 ESC - Blood thinners generate strong data Bayer
  August 31, 2010 ESC - Elinogrel shows its stuff but Brilinta still the star Portola Pharmaceuticals
  August 31, 2010 ESC - Eisai and Relypsa contribute good looking mid-stage candidates Eisai
  August 27, 2010 Roche and ImmunoGen sent reeling by FDA roadblock Roche
  August 27, 2010 Cypress risks deepening disquiet with another spending spree Cypress Bioscience
  August 26, 2010 Somaxon seeks to wake up Silenor launch with P&G alarm clock Somaxon Pharmaceuticals
  August 25, 2010 Gene therapy players sensing light at the end of the tunnel Oxford BioMedica
  August 24, 2010 Kamada upgrades to Baxter to spearhead US move Kamada
  August 23, 2010 Jazz hears adcom sing from different song sheet Jazz Pharmaceuticals
  August 23, 2010 Sanofi most likely to face Pfizer in Genzyme battle as price wrangles continue Sanofi-Aventis
  August 20, 2010 Eli Lilly's glimmers of light unlikely to bring brighter news Eli Lilly
  August 19, 2010 Biogen's deal with Knopp will swell phase III ALS pipeline Knopp Neurosciences
  August 18, 2010 Will gamma secretase Alzheimer's class survive the fall of semagacestat? Eli Lilly
  August 16, 2010 For Aspen and Sigma less is worth more Aspen Pharmacare
  August 13, 2010 Emergent seeks diversity in Trubion purchase Emergent BioSolutions
  August 13, 2010 Eli Lilly needs to win battles like Strattera Eli Lilly
  August 12, 2010 Adcom recommends Potiga approval but will success be resounding? Valeant Pharmaceuticals International
  August 12, 2010 Merck calls a go-slow on oral vernakalant Cardiome Pharma
  August 12, 2010 Amgen will be disappointed with Vectibix failure Amgen
  August 10, 2010 Curis drops on second hedgehog setback but could value be hibernating? Curis
  August 10, 2010 No brainer for Endo as Penwest activists win the day Endo Pharmaceuticals
  August 10, 2010 Elan and Transition undaunted by efficacy findings for Alzheimer's drug Transition Therapeutics
  August 06, 2010 Vectura finds bearing in post-Advair era with GSK deal Vectura
  August 05, 2010 Merck playing catch-up with boceprevir hep C data Merck & Co
  August 04, 2010 Safety concerns continue to drag down mipomersen Isis Pharmaceuticals
  August 04, 2010 Value returns to The Medicines Company with court decision The Medicines Company
  August 03, 2010 Short but sweet public life for Movetis Movetis
  August 03, 2010 Merck continues to play down J&J arbitration but risk remains Merck & Co
  July 30, 2010 Orexigen steps up pace in obesity race Orexigen Therapeutics
  July 30, 2010 Acadia keeping the faith in pimavanserin despite setbacks ACADIA Pharmaceuticals
  July 29, 2010 Brilinta gets yes from adcom but what will FDA say? AstraZeneca
  July 29, 2010 Allos leaves questions unanswered with Folotyn data Celgene
  July 27, 2010 Onyx’s carfilzomib exceeds expectations Onyx Pharmaceuticals
  July 26, 2010 What a moment for Momenta Momenta Pharmaceuticals
  July 26, 2010 Sanofi hungry for deal and Genzyme could be on the menu Sanofi-Aventis
  July 22, 2010 NicOx gets the bad news on naproxcinod NicOx
  July 21, 2010 Roche facing withdrawal of support for Avastin in breast cancer Roche
  July 21, 2010 Safety concerns narrow tanezumab’s potential further Pfizer
  July 20, 2010 Ramius fires warning shot across Cypress’s bow Cypress Bioscience
  July 19, 2010 Gilead hurt by faltering confidence Gilead Sciences
  July 16, 2010 Vivus sheds more weight after Adcom rejection of Qnexa VIVUS
  July 16, 2010 Vernalis suffers another pipeline blow Vernalis
  July 15, 2010 Will FDA pass the buck on key Avandia decision? GlaxoSmithKline
  July 13, 2010 Talk of PregLem IPO could be on the money PregLem
  July 13, 2010 Protalix can wait for Uplyso's FDA review Protalix BioTherapeutics
  July 12, 2010 Is there a beyond for Infinity? Infinity Pharmaceuticals
  July 09, 2010 Kamada wins US approval for new AAT therapy as report prompts controversy Kamada
  July 08, 2010 XenoPort gets aftershock on gabapentin enacarbil XenoPort
  July 08, 2010 Sigma's shareholders face tough choices Sigma Pharmaceuticals
  July 08, 2010 Serono spin-out Poxel raises €16m to fund phase II diabetes studies Merck KGaA
  July 07, 2010 Without partner Karo keeps eprotirome dreams small Karo Bio
  July 02, 2010 Medicare causes another waiting game for Dendreon Dendreon
  July 02, 2010 Rumoured $20bn Sanofi-Aventis swoop could be about diversification Sanofi-Aventis
  July 01, 2010 Arena snares first marketing partner in obesity race Arena Pharmaceuticals
  June 30, 2010 Celgene buys Abraxis for $2.9bn but insists premium is earned Celgene
  June 30, 2010 Astra wins crucial Crestor battle but efficacy debate will continue AstraZeneca
  June 29, 2010 ADA - Roche's diabetes dreams fade as taspo data deteriorates Roche
  June 28, 2010 EP Vantage Exclusive - Actavis scrambling for options as Deutsche posts 'substantial' loan loss Actavis
  June 25, 2010 Cardiome, Pharming and Archimedes receive good news from Europe Cardiome Pharma
  June 24, 2010 FDA deals Merck and SkyePharma different hands on asthma drugs Merck & Co
  June 23, 2010 Diamyd continues winning streak with J&J deal Diamyd Medical
  June 22, 2010 Biovail and Valeant join forces to drive growth Valeant Pharmaceuticals International
  June 21, 2010 Exelixis has much to prove after lead drug ditched for second time Exelixis
  June 21, 2010 Affymax reeling from Hematide safety scare Affymax
  June 21, 2010 GW Pharma wins historic approval GW Pharmaceuticals
  June 18, 2010 Adolor’s pain continues as drugs fail in osteoarthritis trial Adolor
  June 17, 2010 Bayer takes early stage gamble on OncoMed’s cancer stem cell treatment OncoMed Pharmaceuticals
  June 17, 2010 Prickly response as Curis' hedgehog candidate disappoints Curis
  June 16, 2010 Neurocrine wastes no time delivering deal but hurdles remain Neurocrine Biosciences
  June 15, 2010 Campath on fast track to MS approval Genzyme
  June 14, 2010 Glaxo’s cash efficiency drive leaves Pronova reeling Pronova BioPharma
  June 14, 2010 Nexavar needs to win battles to establish broader utility Onyx Pharmaceuticals
  June 11, 2010 Gilenia clears major regulatory hurdle with surprising ease Novartis
  June 09, 2010 TransTech deal shows growing interest in GKA market TransTech Pharma
  June 09, 2010 Asco - Eisai has convincing growth story in eribulin Eisai
  June 08, 2010 Asco - Growing hopes for next generation kinase inhibitors in CML Novartis
  June 08, 2010 Asco – Pfizer basks in glow of crizotinib applause Pfizer
  June 08, 2010 Vantage Point - Elan seen listing EDT in the US amid choppy European markets Elan
Analysis
  Date Headline Company
  September 07, 2010 EP Vantage Interview - Promedior building wide fibrosis platform Promedior
  September 06, 2010 EP Vantage Interview - TiGenix seeking regenerative niche TiGenix
  September 03, 2010 Event - Roche announces timely efficiency drive as Avastin decision looms Roche
  September 03, 2010 Event - Meridia adcom debate primes pump for Lorqess decision Arena Pharmaceuticals
  September 02, 2010 Event - Pradaxa adcom set for wide scrutiny Boehringer Ingelheim
  September 01, 2010 Event - FDA all that stands in AstraZeneca's way on Brilinta AstraZeneca
  August 26, 2010 Preview - ESC to throw up more than just the hot topics Relypsa
  August 26, 2010 Preview - ESC likely to be dominated by oral blood thinners Bayer
  August 25, 2010 Therapeutic focus - Will hopes evaporate as gene therapy pipeline flows? Vical
  August 25, 2010 EP Vantage Interview - AMT hoping to pop the cork with Glybera approval Amsterdam Molecular Therapeutics
  August 24, 2010 Event - Basilea hoping for Christmas bonus Basilea Pharmaceutica
  August 24, 2010 Event - Chelsea hopes new droxidopa trial stands tall Chelsea Therapeutics
  August 20, 2010 Is Lilly in need of a transformational deal? Eli Lilly
  August 20, 2010 Event – Savient's future awaits in Krystexxa approval decision Savient Pharmaceuticals
  August 19, 2010 Therapeutic focus - What are plan B options if A-beta Alzheimer's hypothesis is void? Baxter International
  August 18, 2010 Event - Regeneron hoping to show clear advantages for VEGF Trap-Eye Regeneron Pharmaceuticals
  August 17, 2010 EP Vantage Interview - Pragmatic Evotec takes on metabolic disease Evotec
  August 17, 2010 Event - Forest Labs antibiotic adcom hard to call Forest Laboratories
  August 16, 2010 Therapeutic focus - Vectibix failure leaves few new options for head and neck cancer Merck KGaA
  August 16, 2010 Event - Painful wait for ProStrakan on Abstral ProStrakan
  August 11, 2010 Event - Lilly looks to Cymbalta expansion Eli Lilly
  August 11, 2010 Therapeutic focus - Anti-infectives market shrinking as new superbug fears emerge GlaxoSmithKline
  August 09, 2010 Event – Jazz awaiting unconventional review for fibromyalgia product Jazz Pharmaceuticals
  August 09, 2010 Event - Ironwood has stomach for IBS market Ironwood Pharmaceuticals
  August 06, 2010 Event - Curis and GDC-0449 remain on the rollercoaster Curis
  August 06, 2010 What partnering hopes for the industry's biggest unpartnered R&D assets? Clinical Data
  August 05, 2010 Bayer’s Xarelto hot on the heels of Pradaxa Bayer
  August 04, 2010 Depomed avoids gabapentin lawsuit but road ahead remains rocky Depomed
  August 03, 2010 Event - FDA on parallel track with Europe on Potiga Valeant Pharmaceuticals International
  August 02, 2010 Event - BioMarin seeks PKU franchise with PEG-PAL BioMarin Pharmaceutical
  August 02, 2010 Therapeutic focus – ALS field entering pivotal stage Sanofi-Aventis
  July 30, 2010 Event – Cubist facing crucial patent negotiations Cubist Pharmaceuticals
  July 29, 2010 Teva feeling effects of hybrid model Teva Pharmaceutical Industries
  July 28, 2010 Medicare dialysis rules to re-shape ESA market Amgen
  July 28, 2010 First half 2010 sees a return to more conventional deal values AstraZeneca
  July 27, 2010 Event - Merck's hep C rival boceprevir approaching pivotal period Merck & Co
  July 27, 2010 EP Vantage Interview - Cerenis adds €40m to the HDL debate Cerenis Therapeutics
  July 26, 2010 Therapeutic focus - Anti-thrombotics face a period of change Sanofi-Aventis
  July 23, 2010 Event - Strong Onyx data could fuel well needed rally Onyx Pharmaceuticals
  July 23, 2010 Shionogi puts hopes on HIV integrase inhibitor Shionogi
  July 22, 2010 Which big pharma remains hostage to blockbuster fortune? Roche
  July 22, 2010 EP Vantage Interview - Calistoga eying registration trials with new funds Calistoga Pharmaceuticals
  July 21, 2010 Event - Brilinta has questions to answer AstraZeneca
  July 20, 2010 Vantage Point - Cochrane report polarises the AAT world Talecris Biotherapeutics
  July 19, 2010 Therapeutic focus – Novel HIV approaches continue to suffer lack of interest Gilead Sciences
  July 15, 2010 Therapeutic focus - Avandia's decline and the type 2 diabetes market GlaxoSmithKline
  July 14, 2010 NPS Pharmaceuticals' recovery gathers momentum NPS Pharmaceuticals
  July 14, 2010 EP Vantage Interview - Synta hotting up as Hsp90 data approaches Synta Pharmaceuticals
  July 13, 2010 EP Vantage Interview – New Genmab CEO aiming to turn tide in its favour Genmab
  July 12, 2010 Anti-coagulant products set to flow fastest Roche
  July 09, 2010 Event - Merck looks to Europe for good news on Movectro Merck KGaA
  July 07, 2010 Pharma industry cutting its R&D cloth to more sustainable levels Novartis
  July 07, 2010 Event - Roche approaching high stakes Avastin breast cancer adcom Roche
  July 06, 2010 Event - Transition hoping Alzheimer's drug will rise from the ashes Transition Therapeutics
  July 06, 2010 Therapeutic focus – Hot cancer drug targets in view Sanofi-Aventis
  July 06, 2010 EP Vantage Interview - Chroma on search for second platform deal Chroma Therapeutics
  July 05, 2010 EP Vantage Interview - Merrion partners into the future Merrion Pharmaceuticals
  July 05, 2010 Therapeutic focus - Sanofi snaps up rare upartnered JAK-2 inhibitor Sanofi-Aventis
  July 02, 2010 Mixed bag of small cap winners and losers in first half Questcor Pharmaceuticals
  July 01, 2010 Big pharma continues to struggle in first half, Indian generics consolidate gains Novo Nordisk
  July 01, 2010 Event - End of Avandia saga in sight? GlaxoSmithKline
  June 30, 2010 EP Vantage Interview – Novo shooting for broad use of insulin degludec Novo Nordisk
  June 29, 2010 MolMed investors asked to settle down for long-term growth MolMed
  June 28, 2010 ADA – Experts rally round Lantus Sanofi-Aventis
  June 25, 2010 Sanofi snaffles novel diabetes drug Metabolex
  June 24, 2010 Event - Kamada needs to deliver on Glassia approval promise Kamada
  June 23, 2010 Is Cypress backing the wrong horse? Cypress Bioscience
  June 22, 2010 EP Vantage Interview - ImmunoGen awaiting validation ImmunoGen
  June 18, 2010 Sanofi forced to defend Lantus' safety again Sanofi-Aventis
  June 18, 2010 Roche's diabetes blow prompts Amylin gain Roche
  June 17, 2010 Mystery and intrigue surround change of helm at Genmab Genmab
  June 16, 2010 Event - Vivus shares shed weight over analyst safety concerns ahead of Adcom VIVUS
  June 16, 2010 Relief for Sanofi as Multaq's European prospects improve Sanofi-Aventis
  June 15, 2010 Trubion's RA candidate gets the chop in Pfizer's R&D cull Trubion Pharmaceuticals
  June 11, 2010 Bristol-Myers, Pfizer given reason for cheer with apixaban Bristol-Myers Squibb
  June 11, 2010 EP Vantage Exclusive - Hopp denies Wilex takeover ambitions Wilex
  June 10, 2010 Asco EventAnalyzer - 2010's winners and losers Wilex
  June 10, 2010 Event - Valeant’s recent efforts reduce dependence on retigabine Valeant Pharmaceuticals International
EventAnalyzer - Daily
  Date Headline Company
  September 08, 2010 Daily Market Movers (7 Sep 2010) Taiko Pharmaceutical
  September 07, 2010 Daily Market Movers (6 Sep 2010) Mochida Pharmaceutical
  September 06, 2010 Daily Market Movers (3 Sep 2010) Faes Farma
  September 03, 2010 Daily Market Movers (2 Sep 2010) Orexigen Therapeutics
  September 02, 2010 Daily Market Movers (1 Sep 2010) Novavax
  September 01, 2010 Daily Market Movers (31 Aug 2010) Cipla Medpro South Africa
  August 31, 2010 Daily Market Movers (30 Aug 2010) ImmunoGen
  August 30, 2010 Daily Market Movers (27 Aug 2010) FDC
  August 27, 2010 Daily Market Movers (26 Aug 2010) NeuroSearch
  August 26, 2010 Daily Market Movers (25 Aug 2010) Somaxon Pharmaceuticals
  August 25, 2010 Daily Market Movers (24 Aug 2010) Dong-A Pharmaceutical
  August 24, 2010 Daily Market Movers (23 Aug 2010) Jubilant Organosys
  August 23, 2010 Daily Market Movers (20 Aug 2010) Wockhardt
  August 20, 2010 Daily Market Movers (19 Aug 2010) Wockhardt
  August 19, 2010 Daily Market Movers (18 Aug 2010) NicOx
  August 18, 2010 Daily Market Movers (17 Aug 10) Evotec
  August 17, 2010 Daily Market Movers (16 Aug 2010) Wockhardt
  August 16, 2010 Daily Market Movers (13 Aug 2010) Trubion Pharmaceuticals
  August 13, 2010 Daily Market Movers (12 Aug 2010) China Medical System
  August 12, 2010 Daily Market Movers (11 Aug 2010) Jazz Pharmaceuticals
  August 11, 2010 Daily Market Movers (10 Aug 2010) Evolva Holding
  August 10, 2010 Daily Market Movers (9 Aug 2010) CHA Bio & Diostech
  August 09, 2010 Daily Market Movers (6 Aug 2010) Vectura
  August 06, 2010 Daily Market Movers (5 Aug 2010) Affymax
  August 05, 2010 Daily Market Movers (4 Aug 2010) Dendreon
  August 04, 2010 Daily Market Movers (3 Aug 2010) Movetis
  August 03, 2010 Daily Market Movers (2 Aug 2010) Orexigen Therapeutics
  August 02, 2010 Daily Market Movers (30 Jul 2010) Geron
  July 30, 2010 Daily Market Movers (29 Jul 2010) China Medical System
  July 29, 2010 Daily Market Movers (28 Jul 2010) Zeltia
  July 28, 2010 Daily Market Movers (27 Jul 2010) Fresenius
  July 27, 2010 Daily Market Movers (26 Jul 2010) Nutra Pharma
  July 26, 2010 Daily Market Movers (23 Jul 2010) Momenta Pharmaceuticals
  July 23, 2010 Daily Market Movers (22 Jul 2010) Alexion Pharmaceuticals
  July 22, 2010 Daily Market Movers (21 Jul 2010) VIVUS
  July 21, 2010 Daily Market Movers (20 Jul 2010) MannKind
  July 20, 2010 Daily Market Movers (19 Jul 2010) Cypress Bioscience
  July 19, 2010 Daily Market Movers (16 Jul 2010) Tekmira Pharmaceuticals
  July 16, 2010 Daily Market Movers (15 Jul 2010) Northwest Biotherapeutics
  July 15, 2010 Daily Market Movers (14 Jul 2010) ChemGenex Pharmaceuticals
  July 14, 2010 Daily Market Movers (13 Jul 2010) Orexigen Therapeutics
  July 13, 2010 Daily Market Movers (12 Jul 2010) Medivir
  July 12, 2010 Daily Market Movers (9 Jul 2010) Cheil Jedang
  July 09, 2010 Daily Market Movers (8 Jul 2010) VIVUS
  July 08, 2010 Daily Market Movers (7 Jul 2010) Sigma Pharmaceuticals
  July 07, 2010 Daily Market Movers (6 Jul 2010) GlaxoSmithKline
  July 06, 2010 EventAnalyzer: Daily Market Movers (5 Jul 2010) Dr. Reddy's Laboratories
  July 05, 2010 EventAnalyzer: Daily Market Movers (2 Jul 2010) Genmab
  July 02, 2010 EventAnalyzer: Daily Market Movers (1 Jul 2010) Arena Pharmaceuticals
  July 01, 2010 EventAnalyzer: Daily Market Movers (30 Jun 2010) Abraxis BioScience
  June 30, 2010 EventAnalyzer: Daily Market Movers (29 Jun 2010) Javelin Pharmaceuticals
  June 29, 2010 EventAnalyzer: Daily Market Movers (28 Jun 2010) Cell Therapeutics
  June 28, 2010 EventAnalyzer: Daily Market Movers (25 Jun 2010) SuperGen
  June 25, 2010 EventAnalyzer: Daily Market Movers (24 Jun 2010) OPKO Health
  June 24, 2010 EventAnalyzer: Daily Market Movers (23 Jun 2010) AVEO Pharmaceuticals
  June 23, 2010 EventAnalyzer: Daily Market Movers (22 Jun 2010) Diamyd Medical
  June 22, 2010 EventAnalyzer: Daily Market Movers (21 Jun 2010) Biovail
  June 21, 2010 EventAnalyzer: Daily Market Movers (18 Jun 2010) Amylin Pharmaceuticals
  June 18, 2010 EventAnalyzer: Daily Market Movers (17 Jun 2010) ImmunoGen
  June 17, 2010 EventAnalyzer: Daily Market Movers (16 Jun 2010) Neurocrine Biosciences
  June 16, 2010 EventAnalyzer: Daily Market Movers (15 Jun 2010) Micromet
  June 15, 2010 EventAnalyzer: Daily Market Movers (14 Jun 2010) Genmab
  June 14, 2010 EventAnalyzer: Daily Market Movers (11 June 2010) Cell Therapeutics
  June 11, 2010 EventAnalyzer: Daily Market Movers (10 Jun 2010) PROLOR Biotech
  June 10, 2010 EventAnalyzer: Daily Market Movers (9 Jun 2010) AVANIR Pharmaceuticals
  June 09, 2010 EventAnalyzer: Daily Market Movers (8 Jun 2010) Grifols
  June 08, 2010 EventAnalyzer: Daily Market Movers (7 Jun 2010) Talecris Biotherapeutics
EventAnalyzer - Weekly
  Date Headline Company
  September 06, 2010 Weekly Market Movers (to 3 Sep 2010) Inhibitex
  August 30, 2010 Weekly Market Movers (to 27 Aug 2010) ArQule
  August 23, 2010 Weekly Market Movers (to 20 Aug 2010) Wockhardt
  August 16, 2010 Weekly Market Movers (to 13 Aug 2010) Trubion Pharmaceuticals
  August 09, 2010 Weekly Market Movers (to 6 Aug 2010) Movetis
  August 02, 2010 Weekly Market Movers (to 30 Jul 2010) Arena Pharmaceuticals
  July 26, 2010 Weekly Market Movers (to 23 Jul 2010) Momenta Pharmaceuticals
  July 19, 2010 Weekly Market Movers (to 16 Jul 2010) Northwest Biotherapeutics
  July 12, 2010 Weekly Market Movers (to 9 Jul 2010) VIVUS
  July 05, 2010 EventAnalyzer: Weekly Market Movers (to 2 Jul 2010) Javelin Pharmaceuticals
  June 28, 2010 EventAnalyzer: Weekly Market Movers (to 25 Jun 2010) Biovail
  June 21, 2010 EventAnalyzer: Weekly Market Movers (to 18 Jun 2010) Genmab
  June 14, 2010 EventAnalyzer: Weekly Market Movers (to 11 Jun 2010) PROLOR Biotech